|
Jul 24
|
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
|
|
Jul 23
|
Arcturus Therapeutics to Attend Upcoming Investor Conferences
|
|
Jun 30
|
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
|
|
Jun 23
|
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
|
|
May 15
|
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
|
|
May 13
|
Q1 2025 Arcturus Therapeutics Holdings Inc Earnings Call
|
|
May 13
|
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ...
|
|
May 12
|
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 12
|
Arcturus Therapeutics: Q1 Earnings Snapshot
|
|
May 12
|
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
|
|
Feb 24
|
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
|
|
Feb 17
|
High Growth Tech Stocks In The United States To Watch
|
|
Oct 1
|
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
|
|
Sep 30
|
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
|
|
Sep 30
|
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
|
|
Sep 2
|
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
|
|
Sep 2
|
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
|
|
Aug 27
|
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
|
|
Aug 26
|
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
|
|
Aug 26
|
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
|